Photo of Charles D. Lopez, M.D., Ph.D.

Charles D. Lopez M.D., Ph.D.

  • (503) 494-6594
    • Associate Professor of Medicine School of Medicine
    • Cell and Developmental Biology Graduate Program School of Medicine
    • Cancer Biology Graduate Program School of Medicine

My major research interest is investigating the basic cellular and molecular mechanisms of how tumors form and respond to treatment. By studying how these things work, I hope to find specific molecules that are targets for new cancer treatments. I see patients with gastrointestinal (digestive system) cancers and participate in clinical trials for a variety of gastrointestinal cancers.

Education

  • Ph.D., University of California San Francisco California 1990
  • M.D., University of California San Francisco, 0 1991
  • Residency:

    • University of California Medical Center, San Francisco, 1994
  • Fellowship:

    • Medical oncology, Stanford University Medical Center, 1998
  • Certifications:

    • American Board of Internal Medicine, Medical Oncology

Memberships and associations

  • American Society of Clinical Oncology (ASCO)

Publications

  • "Chemoradiation for locally advanced unresectable pancreatic cancer - What now?" JAMA Oncology In: , Vol. 3, No. 6, 01.06.2017, p. 850-851.
  • "Colorectal Cancer Liver Metastasis : Evolving Paradigms and Future Directions." CMGH Cellular and Molecular Gastroenterology and Hepatology In: , Vol. 3, No. 2, 01.03.2017, p. 163-173.
  • "ΔN-ASPP2, a novel isoform of the ASPP2 tumor suppressor, promotes cellular survival." Biochemical and Biophysical Research Communications In: , Vol. 482, No. 4, 22.01.2017, p. 1271-1277.
  • "Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer." Molecular Cancer Research In: , Vol. 12, No. 6, 2014, p. 924-939.
  • "Safety and Outcomes Following Resection of Colorectal Liver Metastases in the Era of Current Perioperative Chemotherapy." Journal of Gastrointestinal Surgery In: , Vol. 17, No. 12, 12.2013, p. 2133-2142.
  • "Attenuated expression of apoptosis stimulating protein of p53-2 (ASPP2) in human acute leukemia is associated with therapy failure." PLoS One In: , Vol. 8, No. 11, e80193, 27.11.2013.
  • "Putting the pieces together : Necrolytic migratory erythema and the glucagonoma syndrome." Journal of General Internal Medicine  In: , Vol. 28, No. 11, 11.2013, p. 1525-1529.
  • "N terminus of ASPP2 binds to Ras and enhances Ras/Raf/MEK/ERK activation to promote oncogene-induced senescence." Proceedings of the National Academy of Sciences of the United States of America In: , Vol. 110, No. 1, 02.01.2013, p. 312-317.
  • "Lapatinib and gemcitabine for metastatic pancreatic cancer : A phase II study." American Journal of Clinical Oncology: Cancer Clinical Trials  In: , Vol. 34, No. 1, 02.2011, p. 50-52.
  • "New insights into the expanding complexity of the tumor suppressor ASPP2." Cell Cycle In: , Vol. 8, No. 18, 15.09.2009, p. 2871-2876.
  • "Phase II study of calcitriol-enhanced docetaxel in patients with previously untreated metastatic or locally advanced pancreatic cancer." Investigational New Drugs In: , Vol. 27, No. 4, 08.2009, p. 374-378.
  • "Apoptosis-stimulating protein of p53 (ASPP2) heterozygous mice are tumor-prone and have attenuated cellular damage-response thresholds." Proceedings of the National Academy of Sciences of the United States of America In: , Vol. 106, No. 11, 17.03.2009, p. 4390-4395.
  • "E2F1 regulates the base excision repair gene XRCC1 and promotes DNA repair." Journal of Biological Chemistry In: , Vol. 283, No. 22, 30.05.2008, p. 15381-15389.
  • "hADA2a and hADA3 : new players in beta-catenin signaling." Cancer biology & therapy In: , Vol. 7, No. 1, 01.2008, p. 129-130.
  • "hADA2a and hADA3 : New players in β-catenin signaling." Cancer Biology and Therapy In: , Vol. 7, No. 1, 01.2008, p. 131-132.
  • "The p53 pathway promotes efficient mitochondrial DNA base excision repair in colorectal cancer cells." Cancer Research In: , Vol. 66, No. 7, 01.04.2006, p. 3485-3494.
  • "Control of ASPP2/53BP2L protein levels by proteasomal degradation modulates p53 apoptotic function." Journal of Biological Chemistry In: , Vol. 280, No. 41, 14.10.2005, p. 34473-34480.
  • "Apoptosis-stimulating protein of p53-2 (ASPP2/53BP2L) is an E2F target gene." Cell Death and Differentiation In: , Vol. 12, No. 4, 04.2005, p. 358-368.
  • "Apoptosis stimulating protein of p53 (ASPP2) expression differs in diffuse large B-cel and follicular center lymphoma : Correlation with clinical outcome." Leukemia and Lymphoma In: , Vol. 43, No. 12, 01.12.2002, p. 2309-2317.
  • "Groups of p53 target genes involved in specific p53 downstream effects cluster into different classes of DNA binding sites." Oncogene In: , Vol. 21, No. 51, 07.11.2002, p. 7901-7911.
  • "Inhibition of cell death by ribosomal protein L35a." Cancer Letters  In: , Vol. 180, No. 2, 28.06.2002, p. 195-202.
  • "Proapoptotic p53-interacting protein 53BP2 is induced by UV irradiation but suppressed by p53." Molecular and Cellular Biology In: , Vol. 20, No. 21, 2000, p. 8018-8025.
  • "Deregulation of p53-interacting protein 53bp2 by chemotherapy drugs or proteasomal inhibition may modulate chemotherapy-induced cell death." Blood  In: , Vol. 96, No. 11 PART II, 2000.
  • "Unusual topogenic sequence directs prion protein biogenesis." Science In: , Vol. 248, No. 4952, 13.04.1990, p. 226-229.
  • "Non-hydrophobic extracytoplasmic determinant of stop transfer in the prion protein." Nature In: , Vol. 343, No. 6259, 15.02.1990, p. 669-672.

Additional information

Edit profile